Hint mode is switched on Switch off
Cbonds API
Integrate prices, fundamentals and corporate actions into your workflow

Get Global Stock Data via API

  • Prices & history
  • Fundamentals
  • Dividends & corporate actions

Allogene Therapeutics, ordinary share
ALLO, US0197701065

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Allogene Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in
API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Latest quotes

Try in 7-days Trial access

  • Get full online access to the database
  • Use our powerful bond screener
  • Track bond prices from 400+ sources
  • Smart Portfolio Monitoring
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was founded in 2017 and is headquartered ...
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.
  • Issuer
  • Full borrower / issuer name
    Allogene Therapeutics, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ALLO
  • Placement
    11.10.2018
  • Lock up period
    180
  • Number of papers
    18,000,000
  • Volume of raised funds
    324 mln USD
  • Raised funds in USD
    -
  • Placement share
    15.62%
  • Final placement price
    18 USD
  • Price change since placement date
    -100%
  • By capitalization
    2,074.08 mln USD
Other placements of the issuer
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ALLO
  • Placement
    14.05.2024
  • Lock up period
    180
  • Number of papers
    37,931,035
  • Volume of raised funds
    110 mln USD
  • Raised funds in USD
    -
  • Placement share
    18.2%
  • Final placement price
    2.9 USD
  • Price change since placement date
    -38.62%
  • By capitalization
    604.31 mln USD

Indicators

Holders

Related Stock indices

  • NASDAQ Composite
    26,421.41
    Value
    08/09/2026
    Date

Industry Leaders

Registration is required to get access.